DRUG · Unmapped registry intervention
APR-246 (eprenetapopt) + Pembrolizumab
Find medicine records ·
Find other trials using this name
Clinical trial
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
NCT04383938
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedPhase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Bladder Cancerunresolved
Gastric Cancerverified · MONDO: gastric cancer
NSCLCverified · MONDO: non-small cell lung carcinoma
Advanced Solid Tumorunresolved
Interventions
Sponsors & collaborators
Aprea Therapeuticslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04383938 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.